Anson Funds Management LP Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Anson Funds Management LP purchased a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 327,110 shares of the biopharmaceutical company's stock, valued at approximately $540,000. Anson Funds Management LP owned about 0.17% of Esperion Therapeutics at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Capital Advisors Wealth Management LLC boosted its stake in shares of Esperion Therapeutics by 22.9% during the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 5,000 shares during the period. Boomfish Wealth Group LLC grew its stake in shares of Esperion Therapeutics by 17.1% in the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC increased its holdings in shares of Esperion Therapeutics by 26.4% in the second quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company's stock valued at $73,000 after purchasing an additional 6,823 shares during the period. National Bank of Canada FI increased its holdings in shares of Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 10,225 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Esperion Therapeutics by 45.3% during the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 11,658 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Stock Up 4.2 %

ESPR stock traded up $0.14 on Friday, reaching $3.48. 5,857,658 shares of the company's stock were exchanged, compared to its average volume of 6,425,635. The stock has a fifty day moving average of $2.29 and a 200-day moving average of $2.20. The firm has a market cap of $685.68 million, a PE ratio of -5.44 and a beta of 1.01. Esperion Therapeutics, Inc. has a twelve month low of $1.35 and a twelve month high of $3.81.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ESPR shares. StockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday, December 3rd.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.